The present invention generally relates to droplet libraries and to systems and methods for the formation of libraries of droplets. The present invention also relates to methods utilizing these droplet libraries in various biological, chemical, or diagnostic assays.

The present invention generally relates to droplet libraries and to systems and methods for the formation of libraries of droplets. The present invention also relates to methods utilizing these droplet libraries in various biological, chemical, or diagnostic assays.

The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.

The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.

The present invention generally relates to droplet libraries and to systems and methods for the formation of libraries of droplets. The present invention also relates to methods utilizing these droplet libraries in various biological, chemical, or diagnostic assays.

The present invention generally relates to droplet libraries and to systems and methods for the formation of libraries of droplets. The present invention also relates to methods utilizing these droplet libraries in various biological, chemical, or diagnostic assays.

The invention generally relates to performing sandwich assays in droplets. In certain embodiments, the invention provides methods for detecting a target analyte that involve forming a compartmentalized portion of fluid including a portion of a sample suspected of containing a target analyte and a sample identifier, a first binding agent having a target identifier, and a second binding agent specific to the target analyte under conditions that produce a complex of the first and second binding agents with the target analyte, separating the complexes, and detecting the complexes, thereby detecting the target analyte.

The invention generally relates to performing sandwich assays in droplets. In certain embodiments, the invention provides methods for detecting a target analyte that involve forming a compartmentalized portion of fluid including a portion of a sample suspected of containing a target analyte and a sample identifier, a first binding agent having a target identifier, and a second binding agent specific to the target analyte under conditions that produce a complex of the first and second binding agents with the target analyte, separating the complexes, and detecting the complexes, thereby detecting the target analyte.

A pharmaceutical composition is proposed for the elimination of the causative agents of herpes virus infections from macroorganism tissues, including histone deacetylase inhibitors, acyclovir derivatives, epigallocatechin gallate and glycyrrhizin, characterized in that it additionally contains a supramolecular structure of a combination of gator epigalocatechin gallate and galactate epigalocatechol at least two covalent modifying agents.

Also, the composition may include such substances as chorlecalciferol, toll receptor activators acridonoacetic acid, tilorone, zymosan, imidazoquinoline, imiquimod. As modifiers of the structures of epigalocatechin gallate and glycyrrhizin can be used: succinic anhydride, acetic anhydride, propionic anhydride, butane anhydride, acetic-propionic anhydride, acetic-buttanic anhydride, glutaric anhydride, phthalic anhydride, citric anhydride, citric anhydride citric anhydride, isolimonic anhydride, acetyl chloride, acetyl fluoride, propionyl chloride, butyroyl chloride, ethoxyoxalyl monochloride, monochloroacetic acid.

A pharmaceutical composition is proposed for the elimination of the causative agents of herpes virus infections from macroorganism tissues, including histone deacetylase inhibitors, acyclovir derivatives, epigallocatechin gallate and glycyrrhizin, characterized in that it additionally contains a supramolecular structure of a combination of gator epigalocatechin gallate and galactate epigalocatechol at least two covalent modifying agents.

Also, the composition may include such substances as chorlecalciferol, toll receptor activators acridonoacetic acid, tilorone, zymosan, imidazoquinoline, imiquimod. As modifiers of the structures of epigalocatechin gallate and glycyrrhizin can be used: succinic anhydride, acetic anhydride, propionic anhydride, butane anhydride, acetic-propionic anhydride, acetic-buttanic anhydride, glutaric anhydride, phthalic anhydride, citric anhydride, citric anhydride citric anhydride, isolimonic anhydride, acetyl chloride, acetyl fluoride, propionyl chloride, butyroyl chloride, ethoxyoxalyl monochloride, monochloroacetic acid.